Journal of cardiology最新文献_第5页

Association of American Heart Association's Life's Essential 8 and mortality among US adults with and without cardiovascular disease. 美国心脏协会的生命要数和美国有和没有心血管疾病的成年人的死亡率。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-02-03 DOI: 10.1016/j.jjcc.2025.01.015

Ofer Kobo, Gurleen Kaur, Jacqueline E Tamis-Holland, Sarah Zaman, Renée P Bullock-Palmer, Kamala Tamirisa, Martha Gulati, Mamas A Mamas

{"title":"Association of American Heart Association's Life's Essential 8 and mortality among US adults with and without cardiovascular disease.","authors":"Ofer Kobo, Gurleen Kaur, Jacqueline E Tamis-Holland, Sarah Zaman, Renée P Bullock-Palmer, Kamala Tamirisa, Martha Gulati, Mamas A Mamas","doi":"10.1016/j.jjcc.2025.01.015","DOIUrl":"10.1016/j.jjcc.2025.01.015","url":null,"abstract":"Background: Differences in the American Heart Association's Life's Essential 8 (LE8) score and its association with mortality based on the presence of clinically prevalent cardiovascular disease (CVD) has not been assessed previously.Methods: Data from the National Health and Nutrition Examination Survey 2009-2018 were utilized to calculate LE8 scores among adult patients, stratified by the presence of existing CVD. Health metrics were further divided into health behaviors and health factors. Scores were also evaluated based on sex, age, race/ethnicity, and socioeconomic status. Cox proportional hazard models were used to evaluate the association between the levels of cardiovascular health (CVH), estimated using LE8 score, and risk of all-cause and cardiovascular mortality.Results: 25,359 patients were included in the analysis, of which 10.2 % had CVD. Individuals with known CVD had lower overall CVH (55.9 vs. 65.8, p < 0.001), health behaviors (60.6 vs. 67.9, p < 0.001), and health factors (51.3 vs. 63.8, p < 0.001) scores. The lower CVH scores in those with prior CVD persisted after stratification by sex, age, race/ethnicity, and socioeconomic status. When assessing the association of CVH metrics with mortality, for every 10-point increase in LE8 score, there was a significant reduction (17 %-27 %) in all-cause and CV mortality in those with and without CVD.Conclusions: Individuals with known CVD have lower CVH metric scores. Overall, the LE8 score is able to predict future CV outcomes in both individuals with and without CVD and highlights the importance of effective implementation strategies that target health factors and behaviors in primary and secondary prevention populations.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":"155-163"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Milestones in therapeutic and antithrombotic strategies for chronic thromboembolic pulmonary hypertension. 慢性血栓栓塞性肺动脉高压治疗和抗血栓策略的里程碑。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-03-18 DOI: 10.1016/j.jjcc.2025.03.006

Kazuya Hosokawa, Kohtaro Abe

{"title":"Milestones in therapeutic and antithrombotic strategies for chronic thromboembolic pulmonary hypertension.","authors":"Kazuya Hosokawa, Kohtaro Abe","doi":"10.1016/j.jjcc.2025.03.006","DOIUrl":"10.1016/j.jjcc.2025.03.006","url":null,"abstract":"Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition caused by persistent thrombus obstructing the pulmonary arteries, resulting in pulmonary hypertension. Pulmonary endarterectomy remains the gold standard treatment and can provide dramatic improvement in eligible patients. However, approximately 40 % of patients are inoperable. Over the past years, several randomized controlled trials have explored pulmonary vasodilators and balloon pulmonary angioplasty. Based on these trials, a multimodal treatment approach has been established. Balloon pulmonary angioplasty has shown hemodynamic improvement rather than pulmonary vasodilators in randomized controlled trials. Similarly, lifelong anticoagulation therapy is the cornerstone of CTEPH management. While vitamin K antagonists such as warfarin have been the standard recommended by CTEPH guidelines, recent studies, including the CTEPH AC Registry and the KABUKI trial, suggest that direct oral anticoagulants may be safe and effective alternatives. Several ongoing randomized controlled trials aim to refine treatment strategies. The IMPACT-CTEPH trial is investigating whether the initial combination therapy (riociguat + macitentan) is superior to monotherapy before balloon pulmonary angioplasty. The GO-CTEPH trial compares the efficacy of pulmonary endarterectomy and balloon pulmonary angioplasty in eligible patients. The THERAPY-HYBRID-BPA trial is evaluating the need for continued riociguat after balloon pulmonary angioplasty. The FIND-DCR study is evaluating a new imaging modality for the early detection of CTEPH. As research advances, multimodal approaches combining surgical, interventional, and pharmacological treatments are expected to improve patient outcomes and shape the future of CTEPH management.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":"127-133"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac allograft vasculopathy and splenic switch-off: «Off we go»? 同种异体心脏移植血管病变和脾功能关闭：“关闭我们走”？

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-05-27 DOI: 10.1016/j.jjcc.2025.05.009

Giandomenico Bisaccia, Joyce Wong, Chiara Bucciarelli-Ducci

引用次数: 0

Tricuspid regurgitation: Innovation, current landscape, and future perspective of transcatheter tricuspid valve interventions. 三尖瓣反流：经导管三尖瓣干预的创新、现状和未来展望。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-03-17 DOI: 10.1016/j.jjcc.2025.03.009

Atsushi Sugiura, Tetsu Tanaka, Refik Kavsur, Can Öztürk, Johanna Vogelhuber, Miriam Silaschi, Marcel Weber, Sebastian Zimmer, Georg Nickenig

引用次数: 0

Prognostic values of atrial high-rate episodes on mortality risks in CIED patients. 心房高发生率发作对CIED患者死亡风险的预后价值。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-02-14 DOI: 10.1016/j.jjcc.2025.02.010

Phuuwadith Wattanachayakul, Panat Yanpiset, Narathorn Kulthamrongsri, Vitchapong Prasitsumrit, Kevin Bryan Lo, Jakrin Kewcharoen, Sumeet Mainigi

{"title":"Prognostic values of atrial high-rate episodes on mortality risks in CIED patients.","authors":"Phuuwadith Wattanachayakul, Panat Yanpiset, Narathorn Kulthamrongsri, Vitchapong Prasitsumrit, Kevin Bryan Lo, Jakrin Kewcharoen, Sumeet Mainigi","doi":"10.1016/j.jjcc.2025.02.010","DOIUrl":"10.1016/j.jjcc.2025.02.010","url":null,"abstract":"Background: Recent data showed that patients with cardiac implantable electronic devices (CIEDs) who have atrial high-rate episodes (AHRE) have an increased risk of systemic thromboembolism even without a history of atrial fibrillation. However, data regarding the impact of AHRE on mortality outcomes remain conflicting. This study aims to elucidate this relationship by summarizing all available data via systematic review and meta-analysis.Methods: We systematically reviewed MEDLINE and EMBASE from inception to May 2024 to evaluate the association between AHRE and mortality risk in patients with CIED who did not have a history of atrial fibrillation at implantation. We compared all-cause and cardiovascular mortality in patients with AHRE to those without AHRE. Relative risk (RR) or hazard ratio and their 95 % confidence intervals (CIs) were extracted from each study and combined using the generic inverse variance method.Results: A total of 15 cohort studies were included in the meta-analysis. The pooled analysis showed that patients with AHRE had a higher risk of all-cause mortality compared to those without AHRE, with a pooled RR of 1.57 (95 % CI 1.21-2.03; I2 = 67 %; p < 0.001). Similarly, AHRE was associated with higher cardiovascular mortality, with a pooled RR of 1.80 (95 % CI 1.06-3.05; I2 = 49 %; p = 0.03).Conclusions: Our study found that patients with CIEDs who developed AHRE were at a higher risk of all-cause and cardiovascular mortality compared to those without AHRE.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":"194-201"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry. 服用苏比里尔/缬沙坦的患者无症状性低血压的影响：来自REVIEW-HF登记的见解

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-02-14 DOI: 10.1016/j.jjcc.2025.02.012

Wataru Fujimoto, Shingo Matsumoto, Koshiro Kanaoka, Takahito Nasu, Keisuke Kida, Nobuyuki Kagiyama, Shunsuke Ishii, Yukihiro Watanabe, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Hidekazu Tanaka

{"title":"Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.","authors":"Wataru Fujimoto, Shingo Matsumoto, Koshiro Kanaoka, Takahito Nasu, Keisuke Kida, Nobuyuki Kagiyama, Shunsuke Ishii, Yukihiro Watanabe, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Hidekazu Tanaka","doi":"10.1016/j.jjcc.2025.02.012","DOIUrl":"10.1016/j.jjcc.2025.02.012","url":null,"abstract":"Background: Sacubitril/valsartan has unequivocally demonstrated prognostic improvement in patients with chronic heart failure in large-scale randomized controlled trials. However, it remains uncertain whether patients presenting with asymptomatic hypotension have distinct prognoses compared to those with symptomatic hypotension, and there is no consensus on the optimal strategy for managing asymptomatic hypotension.Methods and results: A multicenter retrospective study was conducted, analyzing data from patients initiated on sacubitril/valsartan therapy. The primary outcome was a composite of cardiovascular death or a hospitalization for heart failure. Among 992 patients, 72 patients (7.3 %) experienced symptomatic hypotension, and 122 patients (12.3 %) experienced asymptomatic hypotension within three months. The incidence of primary endpoint for patients who experienced hypotension, regardless of whether it was symptomatic or asymptomatic, was higher than for those who did not experience hypotension (Log-rank p < 0.05). Among patients who experienced asymptomatic hypotension, 23 patients discontinued sacubitril/valsartan within three days after the onset of asymptomatic hypotension. Patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension experienced a significantly higher incidence of primary endpoints compared to those who continued sacubitril/valsartan therapy (Log-rank p = 0.01).Conclusion: The prognosis of patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension during sacubitril/valsartan therapy was poor. It may be beneficial to aim for the continuation of sacubitril/valsartan therapy even after the occurrence of asymptomatic hypotension.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":"202-208"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's reply. 作者的回答。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-05-01 DOI: 10.1016/j.jjcc.2025.04.011

Toshiaki Isogai, Kojiro Morita, Akira Okada, Hideo Yasunaga

引用次数: 0

Helicobacter pylori Infection and Thoracic Aortic Aneurysm: Insights from Mendelian randomization. 幽门螺杆菌感染与胸主动脉瘤：孟德尔随机化的启示。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-08-01 Epub Date: 2025-05-16 DOI: 10.1016/j.jjcc.2025.05.001

Cheng-Zhi Zhang, Can-Ran Lv, Zhuo-Hang Cui, Jiao-Jiao Wang, Jing Zhang, Jian Yang

{"title":"Helicobacter pylori Infection and Thoracic Aortic Aneurysm: Insights from Mendelian randomization.","authors":"Cheng-Zhi Zhang, Can-Ran Lv, Zhuo-Hang Cui, Jiao-Jiao Wang, Jing Zhang, Jian Yang","doi":"10.1016/j.jjcc.2025.05.001","DOIUrl":"10.1016/j.jjcc.2025.05.001","url":null,"abstract":"The association between Helicobacter pylori (H. pylori) infection and the development of thoracic aortic aneurysm (TAA) remains inconclusive. Globally, approximately 58% of the population is infected with Helicobacter pylori. It is typically associated with chronic gastritis, peptic ulcers, and gastric cancer1. Mendall et al. were the first to report a serological correlation between H. pylori seropositivity and coronary heart disease2, a finding that has gradually spurred interest in the potential role of the bacterium in the pathogenesis of cardiovascular diseases. Previous studies have demonstrated an association between H. pylori-specific serotypes and acute ascending aortic dissection, particularly highlighting the chronic infection with the CagA-VacA s1m1 subtype, which is closely linked to an increased risk of aortic rupture3. Recent studies have suggested that the eradication of H. pylori is associated with a reduced incidence of abdominal aortic aneurysm in patients with peptic ulcer disease4. However, the causal relationship between H. pylori seropositivity and TAA remains unclear. In this study, we employed Mendelian randomization (MR) analysis to explore the potential causal link between H. pylori infection and TAA with the aim of providing further evidence supporting their association.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":"209-210"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into gas exchange, pulmonary artery capacity, and postural variations in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. 慢性血栓栓塞性肺动脉高压和肺动脉高压的气体交换、肺动脉容量和体位变化。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-07-30 DOI: 10.1016/j.jjcc.2025.07.010

Yuanyuan Zou, Yi Ding

引用次数: 0

Association of trace element abnormalities and adverse outcomes in patients with acute heart failure. 急性心力衰竭患者微量元素异常与不良结局的关系。

IF 2.6 3区医学

Journal of cardiology Pub Date : 2025-07-25 DOI: 10.1016/j.jjcc.2025.07.009

Shin Nagai, Toru Kondo, Ryota Morimoto, Hiroaki Hiraiwa, Chiaki Mizuno, Asuka Nozaki, Shotaro Komeyama, Kiyota Kondo, Ryota Ito, Shingo Kazama, Toyoaki Murohara

{"title":"Association of trace element abnormalities and adverse outcomes in patients with acute heart failure.","authors":"Shin Nagai, Toru Kondo, Ryota Morimoto, Hiroaki Hiraiwa, Chiaki Mizuno, Asuka Nozaki, Shotaro Komeyama, Kiyota Kondo, Ryota Ito, Shingo Kazama, Toyoaki Murohara","doi":"10.1016/j.jjcc.2025.07.009","DOIUrl":"10.1016/j.jjcc.2025.07.009","url":null,"abstract":"Background: Trace elements, including zinc, copper, and selenium may influence heart failure prognosis due to their roles in mitochondrial function. Previous studies have reported associations between individual trace element abnormalities-such as low serum zinc, high serum copper, and low selenium levels-and adverse clinical outcomes, including reduced exercise capacity in patients with heart failure. However, the impact of multiple trace element abnormalities remains poorly understood. This study aimed to explore the prevalence of these abnormalities, both individually and in combination, and evaluate the association between multiple abnormalities and outcomes in patients with acute heart failure.Methods: We analyzed patients with acute heart failure admitted to the Nagoya University Hospital between January 2012 and May 2024. Zinc, copper, and selenium levels were measured upon admission.Results: Among the 147 patients, 39 % had zinc deficiency, 52 % had copper excess, and 61 % had selenium deficiency. At least one trace element abnormality was observed in 84 % of patients, and two or three abnormalities were observed in 51 % of patients. Patients with multiple abnormalities had lower albumin levels, higher C-reactive protein levels, and lower hemoglobin levels than those without multiple abnormalities. Over a median follow-up of 196 days, all-cause death was more frequently observed in patients with two or three abnormalities than those with zero or one abnormality (adjusted hazard ratio, 3.78, 95 % confidence interval, 1.23-11.6).Conclusions: Multiple trace element abnormalities are common in patients with acute heart failure and are associated with poor clinical outcomes. These findings suggest correcting trace element abnormalities may be a potential target in heart failure management.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0